Market atlas / Alpha-glucosidase / Acarbose

Acarbose (ITP-validated geroprotector)

repurposedsmall-moleculealpha-glucosidase-inhibitionpostprandial-glucosegut-microbiome● postprandial-glucose

Stage by geography

United Kingdom leads by 4 stages. Singapore reached it about 30 years before Israel.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNSGILKRINJP+4 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	class alpha-Glucosidase Inhibitor [EPC]
UK	approved	2018-12-14	indication Indications Acarbose is recommended for the treatment of non-insulin dependent (NINNM) diabetes mellitus in patients inadequately controlled on diet alone, or…
CN	approved	not dated	form Tablet, chemical drug
IN	signal	2008-04-01	not published
JP	RCT	not dated	not published
SG	approved	1994-10-01	form Tablet, oral, prescription only
IL	approved	2025-01-31	indication Treatment of non-insulin dependent diabetes mellitus (NIDDM) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.
KR	approved	1999-12-23	class Diabetes agents [MFDS 03960]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA H20244564. Domestic generics vs imported originator.

34domestic approvals

Forms listed: 4
Product: Acarbose Tablets
Form: tablet
Strength: 100mg
Holder: Zhejiang Jingxin Pharmaceutical
Origin: China
Approved: 2024-07-30
Approval no: NMPA H20244564

1imported approvals

approval count only; per-product detail not captured

Biomarker trends

no biomarker readings yet

Studies

The studies on Acarbose, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C…	IN, KR, SG
Change in fasting blood glucose levels	IN
Change in post-prandial glucose values	IN
Change in Hemoglobin A1c (HbA1c) levels	IN
Data collection on body weight	IN
Data collection on blood glucose	IN
Data collection on Hba1c	IN
Data collection on pre treatment concomitant diseases	IN
Mean change in HbA1c	IN
Incidence of adverse drug reactions (ADRs) and serious adverse events (SAEs)	JP

Connections

Trajectory

1994

MarketSG: approved-other (HSA-registered (Singapore))

HSA:acarbose (1994-10-01) · machine-extracted

1999

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:acarbose (1999-12-23) · machine-extracted

2008

MarketIN: signal (early clinical signal)

NCT01613105 · machine-extracted

2014

Relatedcontrasts with Metformin

Harrison2014 · machine-extracted

2014

ProfileAcarbose (ITP-validated geroprotector)

Harrison2014 · machine-extracted

2018

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:acarbose (product 10000) · machine-extracted

2025

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:acarbose (2025-01-31) · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 3))

NCT00221156 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 3))

NCT01514838 · machine-extracted

2026

MarketSG: signal (clinical trials (highest phase ?))

NCT00909051 · machine-extracted

2026

MarketCN: approved-other (NMPA-approved (domestic + imported))

NMPA:NMPA H20244564 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

ANDA078470 · machine-extracted

Get into the weeds: raw observations + provenance

hsa__dev_acarbose__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: ACARBOSE (GLUCOBAY 50 TABLET 50 mg), first registration 1994-10-01. [HSA Listing of Registered Therapeutic Products]
   source HSA:acarbose (1994-10-01)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

mfds__dev_acarbose__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Acarbose (Glucobay Tab. 100mg), first approval 1999-12-23. [MFDS drug product-approval list]
   source MFDS:acarbose (1999-12-23)  https://nedrug.mfds.go.kr/pbp/CCBGA01

acar_in  2026-06-29  kind=geography_stage  verify=M
   Acarbose: registered early-phase trials in India [NCT01613105]
   source NCT01613105  https://clinicaltrials.gov/study/NCT01613105

acar_edge_metf  2026-06-29  kind=edge  verify=M
   both metabolic geroprotectors, carbohydrate-absorption vs AMPK
   source Harrison2014  https://doi.org/10.1111/acel.12170

acar_facets  2026-06-29  kind=facets  verify=M
   Acarbose facets
   source Harrison2014  https://doi.org/10.1111/acel.12170

acar_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: Acarbose 100 mg Tablets [active substance: acarbose], first authorised 2018-12-14. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:acarbose (product 10000)  https://www.medicines.org.uk/emc/product/10000/smpc

israelmoh__dev_acarbose__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): ACARBOSE 100 MG (ACROSE 100), current registration 2025-01-31. [Israel MoH Drug Registry]
   source IsraelMoH:acarbose (2025-01-31)  https://israeldrugs.health.gov.il/

ctsearch__JP__dev_acarbose  2026-07-10  kind=geography_stage  verify=M
   acarbose: 4 registered trial(s) in JP, highest phase 3 [NCT00221156]
   source NCT00221156  https://clinicaltrials.gov/study/NCT00221156

ctsearch__KR__dev_acarbose  2026-07-10  kind=geography_stage  verify=M
   acarbose: 8 registered trial(s) in KR, highest phase 3 [NCT01514838]
   source NCT01514838  https://clinicaltrials.gov/study/NCT01514838

ctsearch__SG__dev_acarbose  2026-07-10  kind=geography_stage  verify=M
   acarbose: 1 registered trial(s) in SG, highest phase ? [NCT00909051]
   source NCT00909051  https://clinicaltrials.gov/study/NCT00909051

nmpa__dev_acarbose__CN  2026-07-13  kind=geography_stage  verify=M
   NMPA-approved in China (acarbose): 34 domestic approval(s) (e.g. Acarbose Tablets, 100mg, Zhejiang Jingxin Pharmaceutical, China); 1 imported approval(s). Reference NMPA H20244564.
   source NMPA:NMPA H20244564  https://www.nmpa.gov.cn/datasearch/home-index.html

openfda__ANDA078470__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (ACARBOSE); approved, marketed [ANDA078470]
   source ANDA078470  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA078470